Loading clinical trials...
Loading clinical trials...
A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallel-group, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del CFTR Mutation
Conditions
Interventions
LUM/IVA
activated smart device
+1 more
Locations
11
United States
Hartford, Connecticut, United States
Washington D.C., District of Columbia, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Jackson, Mississippi, United States
Albuquerque, New Mexico, United States
Start Date
June 1, 2016
Primary Completion Date
August 1, 2017
Completion Date
August 1, 2017
Last Updated
September 27, 2018
NCT02417740
NCT06616857
NCT02740868
NCT07108153
NCT07303621
NCT07274631
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions